|
|
KinMet 2010
The 2010 KinMet meeting will be held Wednesday, April 7, 2010 from 12 noon to 6pm in Imperial Ballroom B, at the San Francisco Hilton. The ATVB meeting starts the morning of April 8 in the same hotel.
As the program develops it will be available below.
If you would like to present at the KinMet meeting please contact:
Although the meeting format has been centered around these themes, presentations on the metabolism of lipids and other apoproteins are appropriate and most welcome.
See you in San Francisco in April.
For more information about the KinMet Meeting please email.
KinMet 2010 Program...in progress
|
Time |
Modeling |
ApoB Kinetics and Metabolism |
HDL KInetics and Metabolism |
|
|
Chairs: Hugh Barrett & Bob Phair |
Chair: Frank Sacks |
Chair: Ernie Schaefer |
|
12 noon |
|
|
Robert Levy Award Lecture
HDL Metabolism - What the Zebra Has Taught Us About the Horse. Ernie Schaefer, Tufts University
|
|
|
From a Single Lipoprotein Profile to Metabolic Status Parameters Using Computational
Modeling. Daan van Schalkwijk, TNO Quality of Life, Zeist
& Leiden-Amsterdam CDR, Leiden University & Netherlands Bioinformatics
Centre |
Metabolism of apoB, apoC and apoE in patients with chronic kidney disease. Esther Ooi, University of Western Australia |
Modeling HDL subclasses: Experimental design and analysis of tracer data. Hugh Barrett, University of Western Australia |
|
|
If your apoB modeling software estimates any mass to be different from
the average of your measurements, the software is likely to be wrong. Sekhar Ramakrishnan, Columbia
University |
Plasma Lp(a) Metabolism: Disparate Kinetics of ApoB-100 and Apo(a). Peg Diffenderfer, Tufts University |
Serum Opacity Factor: A novel agent with a provocative mechanism for enhancing multiple RCT steps. Corina Rosales and Henry J Pownall, Baylor College of Medicine |
|
|
A simplified mass-action model of cholesterol transport to predict disease phenotype in knock-out mice. Stewart Russell, New York University Medical Center
|
|
An update on the measurement of RCT in vivo. Scott Turner, KineMed, Emeryville |
|
|
|
|
Configurator based dynamic modeling for reverse cholesterol transport. Sam Adhikari, Sysoft Center for Systems Biology and Engineering |
|
|
|
|
CETP inhibitor Torcetrapib improves the severely impaired reverse cholesterol transport of obese insulin resistant CETP-apoB100
transgenic mice. Francois Briand, Physiogenex S.A.S, Labege, France |
|
|
|
|
|
KinMet acknowledges the support provided for this meeting from Isotec.
|
|
|
|
|
Meetings